4//SEC Filing
Longpre Lara 4
Accession 0001415889-24-008316
CIK 0001759425other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 5:40 PM ET
Size
6.7 KB
Accession
0001415889-24-008316
Insider Transaction Report
Form 4
Longpre Lara
Chief Development Officer
Transactions
- Purchase
Common Stock
2019-09-10$10.64/sh+965$10,268→ 105,372 total - Sale
Common Stock
2023-01-09$20.62/sh−1,003$20,684→ 104,369 total
Footnotes (2)
- [F1]The weighted average purchase price for the transaction reported was $10.64, and the range of prices were between $10.20 and $10.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F2]Shares sold to cover tax witholding obligations associated with the vesting of restricted stock units.
Documents
Issuer
Mirum Pharmaceuticals, Inc.
CIK 0001759425
Entity typeother
Related Parties
1- filerCIK 0001780347
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 5:40 PM ET
- Size
- 6.7 KB